The immunobiology of multiple sclerosis: An autoimmune disease of the central nervous system

Neurobiology of Disease

Volumn 6, Issue 3, 1999, Pages 149-166

  Conlon, Paul ^a   Oksenberg, Jorge R ^b   Zhang, Jingwu ^c   Steinman, Lawrence ^d  

^a NEUROCRINE BIOSCIENCES INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CYTOKINE; DNA VACCINE; GLATIRAMER; LYMPHOTOXIN; MYELIN BASIC PROTEIN; SUPERANTIGEN; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; GENE REARRANGEMENT; GENE TECHNOLOGY; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOBIOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

EID: 0032994147     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1999.0239     Document Type: Review

References (139)

1. Acha-Orbea H., Mitchell D. J., Timmerman L., Wraith D. C., Waldor M. K., Tausch G. S., Zamvil S. S., McDevitt H. O., Steinman L. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell. 54:1988;263-273.
2. Allegretta M., Nicklas J. A., Sriram S., Albertini R. J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science. 247:1990;718-721.
3. Allegretta M., Albertini R. J., Howell M. D., Smith L. R., Martin R., McFarland H. F., Brostoff S., Steinman L. Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J. Clin. Invest. 94:1994;105-109.
4. Arnon R. The development of Cop-1 (Copaxone), an innovative drug for the treatment of MS. Immunol. Lett. 50:1996;1-15.
5. Banki K., Colombo E., Siu F. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in MS. J. Exp. Med. 180:1994;1649-1663.
6. Battistini L., Fischer F. R., Raine C. S., Brosanan C. F. CD1b is expressed in MS lesions. J. Neuroimmunol. 67:1997;145-151.
7. Beck J., Rondot P., Catinot L. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in MS: Do cytokines trigger off exacerbations. Acta Neurol. Scand. 78:1988;318-323.
8. Bell R. B., Lindsey J. W., Sobel R. A., Hodgkinson S., Steinman L. Diverse T cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. J. Immunol. 150:1993;4085-4092.
9. Ben-Nun A., Wekerle H., Cohen I. R. Vaccination against autoimmune encephalomyelitis with T lymphocyte line cells reactive against myelin basic protein. Nature. 292:1981;60-61.
10. Bieganowska K. D., Ausubel L. J., Modabber Y., Slovik E., Messersmith W., Hafler D. A. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J. Exp. Med. 185:1997;1585-1594.
11. Bo L., Sawson T. M., Wesselingh S., Mork S., Choi S., Kong P., Hensley, Trapp B. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:1994;778-782.
12. Boccaccio G. L., Steinman L. Multiple sclerosis: From a myelin point of view. J. Neurochem. Res. 45:1996;647-654.
13. Bonetti B., Raine C. S. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42:1997;74-84.
14. Bourdette D. N., Whitham R., Chou Y. K. Immunity to TCR peptides in MS. I. Successful immunization of patients with synthetic Vb5.2 and Vb6.1 CDR2 peptides. J. Immunol. 152:1994;2510-2519.
15. Brenner T., Sobel R., Perez D., Steinman L. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J. Immunol. 158:1997a;2940-2946.
16. Brenner T., Gallily R., Boneh A., Sicsic C., Abramsky O., Steinman L. Involvement of nitric oxide and tumor necrosis factor α in central nervous system demyelination and inflammation. Abramsky O., Ovadia H. Frontiers in Multiple Sclerosis: Clinical Research and Therapy. 1997b;121-127 Martin Dunitz, London.
17. Brocke S., Gaur A., Piercy C., Gautam A., Gijbels K., Fathman C. G., Steinman L. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature. 365:1993;642-644.
18. Brocke S., Gijbels K., Steinman L. Experimental autoimmune encephalomyelitis in the mouse. Cohen I. R., Miller A. Autoimmune Disease Models. 1994a;Academic Press, San Diego.
19. Brocke S., Veromaa T., Weissman I., Gijbels K., Steinman L. Infection and multiple sclerosis: A possible role for superantigens. Trends Microbiol. 2:1994b;250-254.
20. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D., Veromaa T., Waisman A., Gaur A., Conlon P., Ling N., Fairchild P. J., Wraith D. C., O'Garra A., Fathman C. G., Steinman L. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 379:1996;343-345.
21. Brown J., Jardetzky T., Gorga J., Stern L., Urban R., Strominger J., Wiley D. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 364:1993;33-39.
22. Cannella B., Raine C. S. The adhesion molecule and cytokine profile of MS lesions. Ann. Neurol. 37:1995;424-435.
23. Chee M. S., Huang X., Yang R., Hubbell E., Berno A., Stern D. Accessing genetic information with high-density DNA arrays. Science. 274:1996;610-614.
24. Chou Y. K., Morrison W. J., Weinberg A. D. II. Vb5.2 and Vb6.1 CDR2 peptides. J. Immunol. 152:1994;2520-2529.
25. Chung I. Y., Norris J. G., Benveniste E. N. Differential tumor necrosis factor α expression by astrocytes from EAE-susceptible and resistant rat strains. J. Exp. Med. 173:1991;801-811.
26. Cohen I. R., Steinman L. The potential of DNA vaccination. Hospital Pract. 32:1997;169-178.
27. Compston D. A., Morgan B. P., Campbell A. K. Immunocytochemical localization of the terminal complement complex in MS. Neuropathol. Appl. Neurobiol. 15:1989;307-316.
28. Crowe P. D., Van Arsdael T. L., Walter B. N., Ware C. F., Hession C., Ehrenfels B., Browning J. L., Din W. S., Goodwin R. G., Smith C. A. A lymphotoxin-beta specific receptor. Science. 264:1994;707-710.
29. Cuzner M. L. The expression of tissue type plasminogen activator, matrix metalloproteinase inhibitors and endogenous inhibitors in the central nervous system in MS: Comparison of stages in lesion evolution. J. Neuropathol. Exp. Neurol. 55:1996;1194-1204.
30. Dib C., Faure S., Fizames C., Samson D., Drouot N., Vignal A., Millasseau P., Marc S., Hazan J., Seboun E. A comprehensive genetic map of the human genome based on 5,264 microsatellites. Nature. 380:1996;152-154.
31. D'Souza S. D. MS: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184:1996;2361-2370.
32. Ebers G. C., Kukay K., Bulman D. E., Sadovnick A. D., Rice G., Anderson C., Armstrong H., Cousin K., Bell R. B., Hader W., Paty D. W., Hashimoto S., Oger J., Duquette P., Warren S., Gray T., O'Connor P., Nath A., Auty A., Metz L. A full genome search in multiple sclerosis. Nat. Genet. 13:1996;472-476.
33. Lancet. 352:1998;1491-1497.
34. Fierz W., Endler B., Resek K. Astrocytes as antigen presenting cells. I. Induction of Ia antigen expression in astrocytes by T cells via immune interferon and its effect on antigen presentation. J. Immunol. 134:1985;3785-3793.
35. Frei K., Eugster H. P., Bopst M., Constantinuscu C. S., Lavi E., Fonatana A. TNFa and lymphotxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1997;2177-2182.
36. Fujinami R. S., Oldstone M. B. A. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity. Science. 230:1985;1043-1045.
37. Garren H., Steinman L., Lock C. The specificity of the antibody response in MS. Ann. Neurol. 43:1998;4-5.
38. Gaur A., Boehme S. A., Chalmers D., Crowe P. D., Pahuja A., Ling N., Brocke S., Steinman L., Conlon P. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. 74:1997;149-158.
39. Gautam A. M., Liblau R., Chelvanayagam G., Steinman L., Boston T. A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune encephalomyelitis. J. Immunol. 160:1988;5188-5194.
40. Gautam A. M., Pearson C., Smilek D., Steinman L., McDevitt H. O. A polyalanine peptide containing only five native myelin basic protein residues induces autoimmune encephalomyelitis. J. Exp. Med. 176:1992;605-609.
41. Genanin C. P., Cannella B., Hauser S. L., Raine C. S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. 5:1999;170-175.
42. Gijbels K., Masure S., Carton H., Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with MS and other inflammatory neurological disorder. J. Neuroimmunol. 41:1992;29-35.
43. Gijbels K., Galardy R., Steinman L. Reversal of EAE with a hydroxymate inhibitor of matrix metalloproteases. J. Clin. Invest. 94:1994;2177-2182.
44. Gold D. P., Vainiene M., Celnik B., Wiley S., Gibbs C., Hashim G., Vandenbark A., Offner H. Characterization of the immune response to a secondary encephalitogenic epitope of basic protein in Lewis rats. II. Biased TCR Vβ expression predominates in spinal cord infiltrating T cells. J. Immunol. 148:1992;1712-1717.
45. Goverman J., Woods A., Larson L., Weiner L., Hood L., Zaller D. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 72:1993;551-560.
46. Hafler D. A., Saadeh M. G., Kuchroo V. K., Milford E., Steinman L. T cell receptor usage in human and experimental demyelinating disease. Immunol. Today. 17:1996;152-159.
47. Hara H., Morita M., Iwaki T., Hatae T., Itoyama Y., Kitamoto T., Akizuki Si, Gotyo I., Watanabe T. Detection of HTLV-1 proviral DNA and analysis of TCR Vβ CDR3 sequences in spinal cord lesions of HTLV-1-associated myelopathy/tropical spastic paraparesis. J. Exp. Med. 180:1994;831-836.
48. Hattersley A. T. Genes versus environment in insulin dependent diabetes: The phony war. Lancet. 349:1997;147-148.
49. Heller R. A., Schena M., Chai A., Shalon D., Bedilion T., Gilmore J., Wooley D. E., Davis R. W. Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc. Natl. Acad. Sci. USA. 94:1997;2150-2155.
50. Hermans G., Stinissen P., Hauben L., Van den Berg-Loonen E., Raus J., Zhang J. Cytokine profile of MBP-reactive T cells in MS and healthy individuals. Ann. Neurol. 42:1997;18-27.
51. Hofman F. M., Hinton D. R., Johnson K., Merrill J. E. TNF identified in MS brain. J. Exp. Med. 170:1989;607-612.
52. Howell M. D., Winters S. T., Olee T. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides. Science. 246:1989;668-670.
53. Neurology. 43:1993;755-661.
54. Jahnke U., Fischer E. H., Alvord E. A. Sequence homology between certain viral proteins and proteins related to encephalomyelitis and neuritis. Science. 229:1985;282-284.
55. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lesale R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Copolymer-1 reduces relapse rate and improves disability in relapsing remitting MS. Neurology. 45:1995;1268-1276.
56. Karin N., Szafer F., Mitchell D., Gold D., Steinman L. Selective and non-selective stages in homing of T lymphocytes to the central nervous system during experimental allergic encephalomyelitis. J. Immunol. 150:1993;4116-4124.
57. Karin N., Mitchell D., Ling N., Brocke S., Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon-γ and TNF-α production. J. Exp. Med. 180:1994;2227-2237.
58. Karpuj M. V., Steinman L., Oksenberg J. Multiple sclerosis: A polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics. 1:1997;21-28.
59. Korner H., Riminton D. S., Strickland D. H., Lemckert F. A., Pollard J. D., Sedgwick J. D. Critical points of TNF action in CNS autoimmune inflammation defined by gene targeting. J. Exp. Med. 186:1997;1585-1590.
60. Kotzin B., Karuturi S., Chou Y. K. Preferential TCR beta chain variable gene use in MBP-reactive T cell clones from patients with MS. Proc. Natl. Acad. Sci. USA. 88:1991;9161-9165.
61. Kuokkanen S., Sundvall M., Terwilliger P., Tienari P. J., Wikstrom J., Holmdahal R., Petterson U., Peltonen L. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus EAE2. Nat. Genet. 13:1996;477-480.
62. Kuchroo V., Greer J., Kaul D. A single TCR antagonist peptide inhibits experimental autoimmune encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153:1994;3326-3336.
63. Leppert D., Waubant E., Burk M., Oksenberg J. R., Hauser L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40:1996;846-852.
64. Liedtke W., Cannella B., Mazzaccaro R., Clements J., Miller K., Wucherpfennig K., Gearing A. J., Raine C. S. Effective treatment of models of MS by matrix metalloproteinase inhibitors. Ann. Neurol. 44:1998;35-46.
65. Lider O., Reshef T., Beraud E. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science. 239:1988;181-184.
66. Liu J., Marino M. W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A. J., Old L., Bernard C. C. A. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4:1998;78-83.
67. Lobell A., Weissert R., Storch M. K., Svanholm C., de Graaf K. L., Lassmann H., Andersson R., Olsson T., Wigzell H. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med. 187:1998;1543-1548.
68. Lockhart D. J., Dong H., Byrne M. C., Follettie M. T., Gallo M. V., Chee M. S., Mittmann M., Wang C., Kobayashi M., Horton H., Brown E. L. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14:1996;1675-1680.
69. Lucchinetti C. F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicate heterogeneity in pathogenesis. Brain Pathol. 6:1996;259-274.
70. Lupski J. R. Molecular genetics in clinical practice: Charcot Marie Tooth disease: A gene dosage effect. Hospital Pract. 32:1997;83-122.
71. Lupski J. R., Chance P. F., Garcia C. A. Inherited primary peripheral neuropathies: Molecular genetics and clinical implications of CMT1A and HBPP. JAMA. 270:1993;2326.
72. MacKenzie-Grahm A. J., Pribyl T. M., Kim S., Porter V. R., Campagnoni A. T., Voskuhl R. Myelin protein expression is increased in lymph nodes of mice with relapsing EAE. J. Immunol. 159:1997;4602-4610.
73. McCarron R. M., Spatz M., Kempski O. Interaction between myelin basic protein-sensitized T lymphocytes and murine cerebral vascular endothelial cells. J. Immunol. 137:1986;3428-3435.
74. McDonald W. I., Miller D. H., Barnes D. The pathological evolution of MS. Neuropathol. Appl. Neurobiol. 18:1992;319-334.
75. Martin R., Howell M. D., Jaraquemada D., Flerlage M., Richert J., Brostoff S., Long E. O., McFarlin D. E., McFarland H. E. A myelin basic protein peptide is recognized in the context of four HLA DR types associated with MS. J. Exp. Med. 173:1991;19-24.
76. Medaer R., Stinissen P., Truyen L. Depletion of myelin basic protein autoreactive T cells by T cell vaccination: Clinical trial in multiple sclerosis. Lancet. 346:1995;807-808.
77. Merril J. E., Ignarro L. J., Sherman M. P., Melnick J., Lane T. B. Microglia cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 141:1993;2132.
78. Nat. Genet. 13:1996;469-471.
79. Navikas V., He B., Link J. Augmented expression of TNFα and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain. 119:1996;213-223.
80. Nornoha A., Toscas A., Jensen E. IFN-beta down regulates IFN gamma production by activated T cells in MS. Neurology. 41:1991;219-226.
81. Oksenberg J. R. Immunogenetics and heterogeneity in multiple sclerosis. Ann. Neurol. 40:1996;557-558.
82. Oksenberg J. R., Panzara M. A., Begovich A. B., Mitchell D., Erlich H. A., Murray R. S., Shimonkevitz R., Sherritt M., Rothbard J., Bernard C. C. A., Steinman L. Selection for T cell receptor Vβ-Dβ-Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature. 362:1993a;68-70.
83. Oksenberg J. R., Begovich A. B., Erlich E., Steinman L. Genetic factors in multiple sclerosis. JAMA. 270:1993b;2362-2369.
84. Panitch H. S., Hirsch R. L., Schindler J. Treatment of MS with gamma interferon: Exacerbations associated with activation of the immune system. Neurology. 37:1987a;1097-1103.
85. Panitch H. S., Folus J. S., Johnson K. P. Recombinant beta interferon inhibits gamma interferon production in MS. Ann. Neurol. 22:1987b;139-146.
86. Paty D. W., Li D. K. B. Interferon beta-1b is effective in relapsing-remitting MS. II. MRI analysis results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
87. Powell M. B., Mitchell D., Lederman J., Buckmeier J., Zamvil S. S., Graham M., Ruddle N. H., Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2:1990;539-544.
88. Lancet. 352:1998;1498-1504.
89. Pribyl T. M., Campagnoni C. W., Kampf K., Kashima T., Handley V., McMahon J., Campagnoni A. T. The human myelin basic protein gene is included within a 179-kilobase transcription unit: Expression in the immune and central nervous systems. Proc. Natl. Acad. Sci. USA. 90:1993;10695-10699.
90. Probert L., Akassoglou K., Pasparakis M., Kontogeorgos G., Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of TNFα Proc. Natl. Acad. Sci. USA. 92:1995;11294-11298.
91. Racke M. K., Dhib-Jalbut S., McFarland H. Modification of EAE with cytokines. Ann. Neurol. 28:1990;24-31.
92. Rudick R. A., Cohen J. A., Weinstock-Guttman, Kinkel R., Ransohoff R. Management of MS. N. Engl. J. Med. 337:1997;1604-1611.
93. Saruham-Direskeneli G., Weber F., Meinl E. Human T cell autoimmunity against MBP: CD4+ cells recognizing epitopes of the TCR beta chain from an MBP specific T cell clone. Eur. J. Immunol. 23:1993;530-540.
94. Sawcer S., Jones H. B., Feakes R., Gray J., Smaldon N., Chataway J., Robertson N., Clayton D., Goodfellow P. N., Compston A. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13:1996;464-468.
95. Scolding N., Franklin R. Axon loss in MS. Lancet. 352:1998;340-341.
96. Selmaj K. W., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
97. Selmaj K., Raine C. S., Cross A. Anti-TNF therapy abrogates autoimmune demyelination. Ann. Neurol. 30:1991;694-701.
98. Sharief M. K., Hentges R. Association between TNFα and disease progression in patients with MS. N. Engl. J. Med. 325:1991;467-472.
99. Shoemaker D. D., Lashkari D. A., Morris D., Mittmann M., Davis R. W. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet. 14:1996;450-456.
100. Sobel R. A., Mitchell M. E., Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am. J. Pathol. 136:1990;1309-1316.
101. Sobel R. A., Chen M., Maeda A., Hinojoza J. R. Vitronectin and integrin vitronectin receptor localization in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 54:1995;202-213.
102. Steinman L. Autoimmune disease. Sci. Am. 269:1993;106-114.
103. Steinman L. Specific motifs in T cell receptor VβDβJβ gene sequences in multiple sclerosis lesions in brain. Behring Inst. Mitteilungen. 94:1994;148-157.
104. Steinman L. Escape from horror autotoxicus: The pathogenesis and treatment of autoimmunity. Cell. 80:1995a;7-10.
105. Steinman L. Presenting an odd autoantigen. Nature. 375:1995b;739-740.
106. Steinman L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996a;299-302.
107. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: A tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. USA. 93:1996b;2253-2256.
108. Steinman L., Waisman A., Altmann A. Major T cell responses in multiple sclerosis. Mol. Med. Today. 1:1995;79-83.
109. Steinman L., Conlon P. Viral damage and the breakdown of self-tolerance. Nat. Med. 3:1997;1085-1087.
110. Steinman L., Oldstone M. B. A. More mayhem from molecular mimics. Nat. Med. 3:1997;1321-1322.
111. Stuve O., Dooley N., Uhm J., Antel J., Francis G., Williams G., Yong V. Interferon-β decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9. Ann. Neurol. 40:1996;853-863.
112. Suen W., Bergman C. M., Hjelmstrom P., Ruddle N. H. A critical role for lymptoxin in EAE. J. Exp. Med. 186:1997;1233-1240.
113. Tang D., DeVit M., Johnston S. Genetic immunisation is a simple method to elicit an immune response. Nature. 356:1993;152-154.
114. Todd J. A., Steinman L. Autoimmunity. The environment strikes back. Curr. Opin. Immunol. 5:1993;863-865.
115. Tranquill L. R., Skinner E., Campagnoni C., Vergelli M., Hemmer B., Muraro P., Martin R., McFarland H. F., Campagnoni A. T., Voskuhl R. R. Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: Recognition of golli MBP HOG 7. J. Neurosci. Res. 45:1996;820-828.
116. Trapp B. D., Peterson J., Ransohoff R. M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of MS. N. Engl. J. Med. 338:1998;278-285.
117. Traugott U., Lebon P. Demonstration of alpha, beta and gamma interferon in active chronic MS lesions. Ann. N.Y. Acad. Sci. 540:1988a;309-311.
118. Traugott U., Lebon P. Multiple sclerosis: Involvement of interferons in lesion pathogenesis. Ann. Neurol. 24:1988b;245-251.
119. Vandenbark A. A., Hashim G. A., Offner H. Immunization with a synthetic T cell receptor V region peptide protects against experimental autoimmune encephalomyelitis. Nature. 341:1989;541-544.
120. Vandenbark A. A., Chou K., Whitham R. Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial. Nat. Med. 10:1996;1109-1115.
121. van Noort J. M., van Sechel A. C., Bajramovic J. J., el Ouagmiri M., Polman C. H., Lassmann H., Ravid R. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature. 375:1995;798-801.
122. van Stipdonk M. J. B., Willems A. A., Amor S., Peerson-Deen C., Travers P. J., Boeg C. J. P., van Noort J. M. T cells discriminate between differentially phosphorylated forms of aB-crystallin, a major CNS antigen. Int. Immunol. 10:1998;943-950.
123. Waisman A., Ruiz P. J., Hirschberg D. L., Gelman A., Oksenberg J. R., Brocke S., Mor F., Cohen I. R., Steinman L. Suppressive vaccination with DNA encoding a variable region gene of the T cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity. Nat. Med. 2:1996;899-906.
124. Waksman B. More genes versus environment. Nature. 377:1995;105-106.
125. Waxman S. G. Demyelinating diseases - New pathological insights, new therapeutic targets. N. Engl. J. Med. 338:1998;323-325.
126. Warren K. G., Catz I., Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B cell epitope and a model of its unique features. Proc. Natl. Acad. Sci. USA. 92:1995;11061-11065.
127. Warren K. G., Catz I., Wucherpfennig K. W. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope p85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 152:1997;31-38.
128. Weber J. L., May P. E. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am. J. Hum. Genet. 44:1989;388-396.
129. Weissenbach J., Gyapay G., Dib C., Vignal A., Morissette J., Millasseau P., Vaysseix G., Lathrop M. A second generation linkage map of the human genome. Nature. 359:1992;794-801.
130. Windhagen A., Scholz C., Hollsberg P. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity. 2:1995;373-380.
131. Wucherpfenig K. W., Catz I., Hausmann S., Strominger J. L., Steinman L., Warren K. G. Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2 restricted T cell clones from multiple sclerosis patients: Identity of key contact residues in the B-cell and T-cell epitopes. J. Clin. Invest. 100:1997;1114-1122.
132. Wucherpfennig K., Strominger J. Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell. 80:1995;695-705.
133. Yednock T., Cannon C., Fritz L., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 356:1992;63-66.
134. Yu M., Johnson J. M., Tuohy V. K. A predictable sequential determinant spreading cascade invariably accompanies progression of EAE: A basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1996;1771-1778.
135. Zelenika D., Griam B., Pessac B. A new family of transcripts of the myelin basic protein gene: Expression in brain and immune system. J. Neurochem. 60:1993;1574-1577.
136. Zhang J., Medaer R., Stinissen P. MHC restricted clonotypic depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science. 261:1993;1451-1454.
137. Zhang J., Markovic S., Lacet B. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179:1994;973-984.
138. Zhang J., Vandevyver C., Stinissen P. Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens. J. Autoimmun. 8:1995;1-18.
139. Zhang J., Rivera M., Raus J., Steinman L. New treatment for multiple sclerosis. Curr. Neurol. 17:1997;157-189.